These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 31273679)

  • 1. Allocating healthcare resources to genomic testing in Canada: latest evidence and current challenges.
    Weymann D; Dragojlovic N; Pollard S; Regier DA
    J Community Genet; 2022 Oct; 13(5):467-476. PubMed ID: 31273679
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Valuation of Health and Nonhealth Outcomes from Next-Generation Sequencing: Approaches, Challenges, and Solutions.
    Regier DA; Weymann D; Buchanan J; Marshall DA; Wordsworth S
    Value Health; 2018 Sep; 21(9):1043-1047. PubMed ID: 30224107
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Toward Best Practices for Economic Evaluations of Tumor-Agnostic Therapies: A Review of Current Barriers and Solutions.
    Weymann D; Pollard S; Lam H; Krebs E; Regier DA
    Value Health; 2023 Nov; 26(11):1608-1617. PubMed ID: 37543205
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Next-generation sequencing in oncology: challenges in economic evaluations.
    Ehman M; Punian J; Weymann D; Regier DA
    Expert Rev Pharmacoecon Outcomes Res; 2024 Dec; 24(10):1115-1132. PubMed ID: 39096135
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Economic Evaluations of Next-Generation Precision Oncology: A Critical Review.
    Weymann D; Pataky R; Regier DA
    JCO Precis Oncol; 2018 Nov; 2():1-23. PubMed ID: 35135140
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A scoping study to explore the cost-effectiveness of next-generation sequencing compared with traditional genetic testing for the diagnosis of learning disabilities in children.
    Beale S; Sanderson D; Sanniti A; Dundar Y; Boland A
    Health Technol Assess; 2015 Jun; 19(46):1-90. PubMed ID: 26132578
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genome-Wide Sequencing for Unexplained Developmental Disabilities or Multiple Congenital Anomalies: A Health Technology Assessment.
    Ontario Health (Quality)
    Ont Health Technol Assess Ser; 2020; 20(11):1-178. PubMed ID: 32194879
    [TBL] [Abstract][Full Text] [Related]  

  • 8. International comparison of comparative effectiveness research in five jurisdictions: insights for the US.
    Levy AR; Mitton C; Johnston KM; Harrigan B; Briggs AH
    Pharmacoeconomics; 2010; 28(10):813-30. PubMed ID: 20831289
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Methodological Issues in Assessing the Economic Value of Next-Generation Sequencing Tests: Many Challenges and Not Enough Solutions.
    Phillips KA; Deverka PA; Marshall DA; Wordsworth S; Regier DA; Christensen KD; Buchanan J
    Value Health; 2018 Sep; 21(9):1033-1042. PubMed ID: 30224106
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical pharmacogenomics testing in the era of next generation sequencing: challenges and opportunities for precision medicine.
    Ji Y; Si Y; McMillin GA; Lyon E
    Expert Rev Mol Diagn; 2018 May; 18(5):411-421. PubMed ID: 29634383
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical Next Generation Sequencing for Precision Medicine in Cancer.
    Dong L; Wang W; Li A; Kansal R; Chen Y; Chen H; Li X
    Curr Genomics; 2015 Aug; 16(4):253-63. PubMed ID: 27006629
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The future of Cochrane Neonatal.
    Soll RF; Ovelman C; McGuire W
    Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Individual health services.
    Schnell-Inderst P; Hunger T; Hintringer K; Schwarzer R; Seifert-Klauss VR; Gothe H; Wasem J; Siebert U
    GMS Health Technol Assess; 2011; 7():Doc05. PubMed ID: 21966301
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Using "Big Data" in the Cost-Effectiveness Analysis of Next-Generation Sequencing Technologies: Challenges and Potential Solutions.
    Wordsworth S; Doble B; Payne K; Buchanan J; Marshall DA; McCabe C; Regier DA
    Value Health; 2018 Sep; 21(9):1048-1053. PubMed ID: 30224108
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Informative value of Patient Reported Outcomes (PRO) in Health Technology Assessment (HTA).
    Brettschneider C; Lühmann D; Raspe H
    GMS Health Technol Assess; 2011 Feb; 7():Doc01. PubMed ID: 21468289
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Economic evaluations of exome and genome sequencing in pediatric genetics: considerations towards a consensus strategy.
    Olde Keizer RACM; Henneman L; Ploos van Amstel JK; Vissers LELM; Frederix GWJ
    J Med Econ; 2021 Nov; 24(sup1):60-70. PubMed ID: 34915793
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Next-generation sequencing in NSCLC and melanoma patients: a cost and budget impact analysis.
    van Amerongen RA; Retèl VP; Coupé VM; Nederlof PM; Vogel MJ; van Harten WH
    Ecancermedicalscience; 2016; 10():684. PubMed ID: 27899957
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Health technology assessment and personalized medicine: are economic evaluation guidelines sufficient to support decision making?
    Husereau D; Marshall DA; Levy AR; Peacock S; Hoch JS
    Int J Technol Assess Health Care; 2014 Apr; 30(2):179-87. PubMed ID: 24806420
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gene expression profiling for guiding adjuvant chemotherapy decisions in women with early breast cancer: an evidence-based and economic analysis.
    Medical Advisory Secretariat
    Ont Health Technol Assess Ser; 2010; 10(23):1-57. PubMed ID: 23074401
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Economic evaluations conducted by Canadian health technology assessment agencies: where do we stand?
    Tarride JE; McCarron CE; Lim M; Bowen JM; Blackhouse G; Hopkins R; O'Reilly D; Xie F; Goeree R
    Int J Technol Assess Health Care; 2008; 24(4):437-44. PubMed ID: 18828938
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.